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AbstrACt
Introduction Topical corticosteroids (TCS) of different 
potencies are the main treatment to control atopic 
dermatitis (AD). The Dutch guideline on AD for general 
practitioners (GPs) recommends a stepwise approach in 
which treatment steps are tailored to the severity of the 
disease, starting with the lowest possible potency of TCS. 
However, it remains unclear whether the recommended 
stepwise approach is most efficient. This randomised 
open-label controlled trial aims to determine whether a 
potent TCS is more effective than a low-potency TCS in the 
initial treatment of children with a moderate flare-up of AD 
in primary care. In the observational cohort, the overall aim 
is to determine the frequency, burden and determinants of 
flare-ups of AD during follow-up.
Methods and analysis The study is an observational cohort 
study with an embedded pragmatic randomised controlled, 
open-label trial. Eligible are patients diagnosed with AD (aged 
12 weeks to 18 years) who visited the GP for AD or received 
repeated prescriptions for AD in the previous 12 months; 
follow-up of the cohort is 1 year. Children are enrolled in 
the trial if they have a flare-up of AD during follow-up in the 
cohort. Eligible children are randomised to the intervention 
group (with a potent TCS once daily) or to the GP guideline 
group (with a low potency TCS once daily). Primary outcome 
is the difference in average subjective disease severity over 
24 weeks follow-up in the trial, measured with the patient-
oriented eczema measure. As secondary outcome, the 
Eczema Area and Severity Index is measured.
Ethics and dissemination This study tests the hypothesis 
that immediate treatment with a potent TCS during a flare-
up of AD leads to faster and more efficacious results as 
compared with starting with a TCS with low potency with 
less overall use of TCS. The study protocol is approved 
by the Medical Ethics Committee (MEC) of the Erasmus 
Medical Center Rotterdam, the Netherlands (MEC-
2017–328). The results of the study will be published in 
international peer-reviewed journals and presented at 
national and international conferences.
trial registration number NTR: 6679; Pre-results.
IntroduCtIon
Atopic dermatitis (AD) or eczema is a 
chronic, highly pruritic inflammatory skin 
disease and one of the most common skin 
disorders in children.1 Eczema is in the top 
10 of the most prevalent disorders in general 
practice in children aged up to 18 years.2 The 
prevalence of AD has increased over the past 
30 years.3 It is estimated that 10%–20% of 
children and 1%–3% of adults in developed 
countries are affected by the disorder.4 In the 
Netherlands, cumulative incidence of AD at 
age 18 years is at least 24%.5 AD often starts 
in early infancy; about 45% of all cases begin 
within the first 6 months of life, 60% during 
the first year and 85% before 5 years of age.6 
AD is associated with (later) occurrence of 
asthma and allergic rhinitis.5 
strengths and limitations of this study
 ► This is the first study to investigate the effectiveness 
of initial treatment with topical corticosteroids class 
I versus class III for long-term control of atopic der-
matitis in children in primary care.
 ► Pragmatic treatment strategy in real-life clinical 
practice.
 ► Study is performed in general practice, where most 
children with eczema are treated.
 ► Cohort study on determinants of flare-up and dis-
ease burden of atopic dermatitis in children.
 ► This randomised open-label trial may be prone to 
observation bias.
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The disorder results in significant morbidity and 
adversely affects quality of life (QoL). Factors that 
contribute to a poor QoL are fatigue, itch, activity 
restriction, depression and sleep deprivation.7 
Approximately, 47%–60% of children with AD expe-
rience sleep disturbance,8 and children with AD and 
their parents can lose about 1–2 hours of sleep/night.9 
Therefore, AD affects social functioning and psycho-
logical well-being, and has an even greater impact 
than diabetes on families of young patients.9 10 This 
includes direct and indirect financial costs, time spent 
on treatment, sleep deprivation (1–2 hours/night) 
and physician visits.
Since there is no definitive cure for eczema, 
suppressive treatment aims to control the disease. The 
majority of patients in general practice control their 
symptoms by application of emollients accompanied 
by symptomatic anti-inflammatory therapy consisting 
of topical corticosteroids (TCS).11 The Dutch guide-
line on AD for general practitioners (GPs) advocates 
a stepwise approach in which treatment steps are 
tailored to the severity of the disease, as determined 
using the Three Item Severity (TIS) score.12 The 
choice of potency of corticosteroids is determined by 
estimating the required effect. When AD is mild to 
moderate, a mild (class I) to moderate potent (class 
II) TCS is preferred, while potent (class III) TCS is 
used only when AD is severe. When treatment is 
insufficient, a higher class can be used. Due to safety 
concerns, the Dutch GP guideline recommends to use 
the lowest potency possible that will still be effective 
to treat the eczema. Potential local side effects of TCS 
are telangiectasia, atrophy, hypopigmentation and 
striae. However, the review of Siegfried et al showed 
no evidence of atrophy and supported the long-term 
safety of low and moderate TCS.13 Potential systemic 
effects of TCS may include suppression of the hypo-
thalamic–pituitary–adrenal (HPA) axis, and osteo-
porosis, glaucoma, cataract and growth reduction. 
Nevertheless, osteoporosis and growth reduction are 
not reported in studies with long-term follow-up.13–15
The existing trials on the efficacy of TCS in chil-
dren are often outdated and of inferior quality with 
only a short follow-up.16–18 However, they indicate 
that more potent TCS may result in faster and better 
disease control in AD; nevertheless, it is not clear 
which initial treatment strategy (ie, mild or potent 
TCS) is the best.12 19 During a flare-up, treatment with 
a potent TCS might lead to faster and better results 
as compared with starting with a mild TCS, with even-
tually less overall use of TCS. Besides improvements 
in disease control and patients’ satisfaction, this may 
also lead to fewer medical consultations and prescrip-
tions, and may therefore be more cost effective. The 
present study focuses on these gaps and hopes to make 
an important contribution to knowledge regarding 
the use of TCS in children with AD treated in general 
practice.
objectives
To determine whether initial treatment with a potent TCS 
is more effective than a mild TCS in the treatment of chil-
dren with a moderate flare-up of AD in primary care in 
the short (ie, 1 week and 4 weeks of follow-up) and long-
term (ie, 6 months follow-up) control of the disease.
In the observational cohort, the aim is to determine the 
frequency and determinants of flare-ups of AD. Further-
more, we will explore the burden of AD by measuring 
severity, medication use, healthcare use and QoL during 
1-year follow-up.
study design
The Rotterdam Eczema study is an observational cohort 
study with an embedded pragmatic randomised open-
label superiority trial with two groups and a patient-re-
ported primary outcome of long-term control. See 
flow chart in figure 1.
Methods; participants, interventions and outcomes
Healthcare system
The GP plays a key role in the Dutch healthcare system 
and (almost) everybody is registered with a GP practice. 
Diagnosis and treatment of eczema, also in children, are 
part of general practice. In case of diagnostic or treatment 
problems in children with eczema, referral to secondary 
care is available; however, referral to a dermatologist is 
not possible without the consent of a GP.
Study setting
Children will be recruited from general practices located 
in the Western part of the Netherlands. The GPs will 
perform a search in their information system to identify 
potentially eligible children.
Eligibility criteria
To be eligible to participate in the cohort study, a child 
must meet all of the following criteria: aged between 
Figure 1: Flow chart of the study. AD, atopic dermatitis; 
EASI, Eczema Area and Severity Index; GP, 
general practitioner; PGA, patient global assessment; POEM, 
patient-oriented eczema measure; TCS, topical corticosteroid. 
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12 weeks and 18 years, diagnosis of eczema (International 
Classification of Primary Care (ICPC) code S87 and S88 
or prescription of topical treatment for eczema) plus 
confirmation of the diagnosis by the GP, a consultation 
or repeated prescription in the previous 12 months and 
informed consent. This will be checked by the own GP 
and the researcher. Exclusion criteria for the cohort study 
are: as determined by the own GP. The own GP will check 
the list of selected children, the own GP is aware of poten-
tial problems limiting participation in a trial like family 
problems, for example, circumstances such as ongoing 
problems due to divorcing parents, relevant psychosocial 
problems, a seriously ill family member or if the child has 
serious comorbidities (eg, intellectual disability). Further-
more, exclusion criteria are: currently under treatment 
with a dermatologist, contraindications for the study 
medication, language barrier or no access to the internet 
(necessary to fill in weekly online questionnaire).
The inclusion criteria for the trial part of the study are: 
participation in the cohort, flare-up (ie, need to inten-
sify topical treatment) from the child’s and/or parents’ 
point of view, a TIS score from ≥3 to <6. Exclusion criteria 
for the trial part are: use of TCS in the 2 weeks before 
inclusion in the trial, AD on eyelid(s), >50% of body 
affected by AD, other skin disorders hampering proper 
assessment of eczema, pregnancy and or breast feeding, 
or untreated skin infections based on clinical signs and 
symptoms (bacterial, viral, fungal or parasitic).
Interventions
Eligible children will participate in the trial part if they 
have a flare-up of AD. They will be randomised to either 
the intervention group or to the GP guideline group 
(control group). Those allocated to the intervention 
group will receive a potent TCS class III once daily to 
start with at each flare-up during the follow-up period 
of the trial. If children are aged >2 years, they will follow 
a predefined weaning-off scheme (ie, reduction of 
frequency) when their symptoms have improved. If chil-
dren are aged <2 years, they will be reassessed by the GP 
after 1–2 weeks. When AD is improved but still needs treat-
ment, children will be treated according to the Dutch GP 
guideline (ie, switch to a less potent TCS).
Children in the control group will receive care as stated 
in the Dutch GP guideline for all flare-ups during the 
trial period. First, they will start with a mild TCS class I 
once daily. When not improved within 1–2 weeks, a mild 
potent TCS class II once daily will be prescribed. When 
class II does not improve symptoms within 1–2 weeks, a 
potent TCS class III will be prescribed once daily. When 
symptoms do improve, children will follow a predefined 
weaning-off scheme.12
In the present study, hydrocortisone acetate cream 1%, 
and triamcinolone acetonide cream 0.1% will be used as 
class I and class II TCS, respectively, since this is a recom-
mended preparation in the national guideline.12 For 
class III TCS, fluticasone propionate cream 0.05% will 
be used; this cream was chosen since it has a relatively 
short half-time as compared with the class III TCS recom-
mended by the national guideline (ie, betamethasone).12 
and is expected to limit potential side effects. Children 
will receive the prescription from their own GP and will 
obtain the prescribed medication from the child’s own 
pharmacy.
Besides the use of corticosteroids, all children (control 
and intervention group) will always be advised to use indif-
ferent therapy with a standard emollient (ie, ‘cetomac-
rogol’). The advice is to use the emollients daily.
Patient and public involvement
The recommendations in the Dutch guideline are based 
on scientific research. It appears, however, that research to 
support recommendations is sometimes lacking or inad-
equate. The Dutch guideline states as a knowledge gap 
(‘lacunebak’) that it is not clear which treatment strategy, 
mild or potent TCS, is best when treating a flare-up of 
AD.12 This stated knowledge gap resulted in the research 
question of our study.
The outcome measures are based on the recommenda-
tions stated by the Harmonising Outcome Measures for 
Eczema (HOME)-initiative. During the development of 
the core outcome set and its measurement tools by this 
initiative, patients have been intensively involved.
The burden of the intervention is similar to the control 
group, both groups will use cream. Therefore, the burden 
of the intervention was not specifically discussed with 
patients.
Study participants will be informed about the results by 
a simplified summary send by email.
outcomes
Primary outcome measure
The primary outcome will be changed in disease severity 
over 24 weeks follow-up in the trial, as measured by the 
average score of the patient-oriented eczema measure 
(POEM). POEM is a patient-reported outcome based on 
symptoms over the previous week, which can be self-com-
pleted by the child’s parent or the child. POEM is a vali-
dated questionnaire and has been recommended by the 
HOME initiative as the preferred instrument to capture 
patient-reported symptoms in eczema trials.20 The POEM 
score is collected weekly in the trial part over 24 weeks and, 
to measure long-term control, the difference between the 
two treatment groups in the average POEM scores will be 
measured over these 24 weeks.
Secondary outcome measures
The Eczema Area and Severity Index (EASI) will be used 
as objective measurement of the AD. The EASI has been 
identified by the HOME initiative as the core outcome 
measurement instrument to evaluate clinical signs of AD 
in all future trials investigating interventions for AD.21 
The EASI is scored by a physician and rates both the 
intensity and extent of AD signs. The EASI will be used as 
secondary outcome in both the trial and the cohort study. 
The EASI score is collected at baseline, and at weeks 1, 4 
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and 24 of the trial, and at baseline, and at weeks 26 and 52 
in the cohort study. See table 1 for an overview of observa-
tions made during the study.
Other secondary outcomes in the trial part include: (1) 
changes in disease severity after 1 week and 4 weeks using 
POEM, (2) QoL using the Infants’ Dermatitis Quality 
of Life Index (IDQOL) or Children’s Dermatology Life 
Quality Index (CDLQI) (depending on age), (3) medi-
cation compliance (determined as a POEM >8 and use 
of TCS during that week), (4) local side effects (painful 
application, telangiectasia, atrophy, hypopigmentation 
and striae), (5) time to recovery (ie, time till start wean-
ing-off treatment), (6) frequency of flare-ups, (7) medi-
cation use (subjective and objective), (8) patient global 
assessment and investigator global assessment (both on a 
6-point scale; clear, almost clear, mild, moderate, severe, 
very severe), (9) itch intensity score (the numeric rating 
scale-11 is ranging from 0, no itch to 10, worst itch imag-
inable) and (10) healthcare use (ie, telephone contact 
with GP, consultation at the general practice or referral 
to secondary care).
The QoL questionnaires are the IDQOL and CDLQI: 
both are validated and widely used in dermatology as a 
QoL scale for children aged ≤4 years and aged 4–16 years, 
respectively.22 23 The use of medication will be registered 
by weighing the tube of TCS after 1 week, 4 weeks and 
24 weeks in the trial. Furthermore, in the weekly ques-
tionnaire, the children will register the number of days 
that TCS and neutral ointment were used in the previous 
week.
The aim of the observational cohort is to determine 
the frequency and determinants of flare-ups of AD after 
1-year follow-up.
Secondary outcomes concerning the cohort includes 
disease severity at inclusion, and at 26 weeks and 52 weeks 
follow-up using POEM and EASI, QoL, frequency of 
flare-ups, medication use and healthcare use.
sample size
In this study, we based our sample size calculation on 
the minimal clinically important difference (MCID) of 
the POEM in young children with eczema as determined 
by Gaunt et al.24 The MCID is the smallest change in an 
outcome measure that represents a clinically relevant 
outcome. A treatment effect of 3.0 POEM points was 
considered clinically relevant. We used a mean of 128.8 
(SD of 5.9) as presented in trials with a similar popu-
lation (ie, primary care patients) on baseline POEM 
characteristics.24
Taking these numbers into account, with a power of 
80% and a=0.05 (two sided), we need 61 children per trial 
group. Assuming a drop-out rate of 15% during the study, 
72 children per treatment arm are required.
recruitment
Based on Dutch GP data and an expected patient partici-
pation of 50%, per participating GP, we expect to include 
seven children per year for the cohort, and four in the 
trial (based on flare-ups).2 Therefore, we expect to need 
about 36 participating GPs. First, we will collaborate with 
our academic network named PRIMEUR. The academic 
PRIMEUR network includes 13 centres with about 97 
participating GPs and about 160 000 patients. If the inclu-
sion is behind expectations, more GPs will be invited to 
participate in the study. Furthermore, if inclusion still 
remains behind expectations using the search protocol 
(eg, consultation, or repeated prescription in the previous 
12 months), we will expand the search period from 12 to 
24 months.
Children will be recruited from general practices. When 
a GP decides to participate, the GP will perform a search 
in their information system to identify all possible eligible 
children. Invitation letters to participate (in the name of 
the GP) will be sent to the parent/carer of the children.
Children are asked to respond using a response card 
or response email, irrespective of whether or not they 
are willing to participate. These responses are sent to the 
coordinating researcher of the department of General 
Practice, Erasmus Medical Center Rotterdam.
After receiving a positive response from the child, 
the research assistant will have telephone contact with 
the child (this can be with the parents if the child is 
aged ≤12 years or the children themselves). During this 
telephone contact, additional information on the study 
and study procedures will be explained. Based on the 
telephone contact, if the child is eligible and is still inter-
ested in participating, the patient information letter (PIF) 
will be sent by mail. Afterwards, if the child is willing to 
participate, the informed consent will be signed by the 
parents (if the child is aged ≤16) or the child (when 
aged ≥12 years) and sent to the department of general 
practice.
After receiving the signed PIF, the research assistant 
will contact the general practice of the child to inform 
them about the child’s participation. The GP practice will 
contact the parents of the child to arrange a consultation. 
During this first consult with the physician assistant, the 
baseline EASI will be obtained.
Assignment of interventions
When the AD flares up, the child (or the child’s parents) 
has to make an appointment by the GP. The definition of 
a flare-up is the need to intensify topical treatment from 
the patient’s and/or parents’ point of view
If the child has a flare-up of AD and is eligible for inclu-
sion in the trial, the child will be randomly allocated to 
one of the two groups by the physician assistant of their 
own GP, using the data management system (research 
manager). The randomisation list will be computer gener-
ated and unknown to the investigators.
Children will be stratified by TIS score (ie, TIS score 
3–5) to ensure equal distribution of the severity of AD 
between the intervention and control group. Random 
permuted blocks of two will be generated. The GP will 
prescribe the medication of randomisation.
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data collection and methods
Data collection of the patient-reported outcomes and 
the objective reported outcomes will be carried out using 
online case report forms. Children (or the child’s parents) 
will receive a reminder by email if questionnaires are not 
filled in after a standardised interval of 3 days. If ques-
tionnaires are not filled in at key time points, participants 
will receive a telephone reminder. Children will receive a 
small gift after completing the cohort or trial follow-up. 
The weekly questionnaires include a question on who 
completed the questionnaire, the child, the parent or 
together. We can, therefore, take into account by whom 
the questionnaire has been completed in our analysis. 
If patients are 16 years or older, they will complete the 
questionnaires themselves. Children under 16 are free in 
their choice to complete the questionnaire themselves or 
together with/by a parent. The physician assistants will 
received additional training in the pathophysiology and 
treatment of AD and in scoring the EASI.
data management
Data will be handled confidentially and anonymously. A 
child’s identification code is used to link the data to the 
child; a unique code is randomly generated for each indi-
vidual. The principal investigator safeguards the key to 
the code.
The software program research manager will be used 
for the online questionnaires and the children’s personal 
data, respectively.
statistical methods
All analyses of the primary study parameters will be 
performed according to the intention-to-treat principle, 
that is, irrespective of compliance. Those who perform 
the analyses will be kept blind regarding which group has 
received what kind of treatment.
Secondary, a per-protocol analysis, excluding children 
in whom major violations of the protocol have occurred, 
will also be performed. Major protocol violations are: 
withdrawal from study or lost to follow-up, and medica-
tion compliance <75%.
In case major events occur during the study period that 
necessitate withdrawal from study, or lost to follow-up/
drop-out for other reasons, weekly diary card data will 
be evaluated up to the week of such drop-out. However, 
children are requested to agree with further follow-up 
according to the study protocol (eg, weekly question-
naires). Medication compliance <75%, (also called 
non-compliance) is determined as a POEM >8 and no use 
of TCS during that week; the compliance is determined 
per week.
For the primary outcome, statistical comparison 
between the treatment groups will be done using analysis 
of covariance (ANCOVA) including the covariates: base-
line symptom score, age and gender. Treatment effects 
will be tested two sided with a significance level of 5%.
For the main study parameter, it is essential that the 
weekly diaries are filled in adequately. However, in case 
of missing data, these will be imputed using multiple 
imputation; this is considered the most appropriate 
way of dealing with missing data.25 Missing values of the 
POEM will be imputed 10 times using the multivariate 
imputation by chained equations logarithm (R-Project). 
The imputation model included sex, age, type of medica-
tion used and frequency of application, and the outcome 
measure POEM.
Secondary outcomes of the trial, statistical comparison 
between the treatment groups for changes in disease 
severity, and QoL after 1 week and 4 weeks, will be 
performed using ANCOVA, including the covariates base-
line symptom score, age and gender. The other secondary 
outcomes (ie, local side effects, systemic side effects, 
compliance, frequency of flare-ups, medication use and 
healthcare use) will be analysed with linear or logistic 
regression when appropriate. For the time to recovery, 
Cox regression analyses will be performed.
To explore differences in patient and disease character-
istics in the two treatment arms, and to determine which 
factors are related to compliance to the two treatment 
strategies, backward logistic regression will be used.
Patient characteristics to be examined are: age, sex, age 
at presentation of AD, history of atopy (ie, asthma, allergic 
rhinitis, food allergy and anaphylaxis), use of other corti-
costeroid(ie, nasal, inhaled, oral) and QoL (IDQoL, 
CDLQI). Disease characteristics are disease severity 
(POEM and EASI), duration of AD, location of AD (ie, 
head and neck, upper limbs, lower limbs and trunk, all 
extracted from EASI) and previous medical care (ie, no 
previous treatment, GP only, GP and secondary care).
To explore which factors are related to compliance to 
the two treatment strategies, backward logistic regres-
sion will be used. The factors to be explored are treat-
ment arm, age, sex, age at presentation of AD, disease 
severity (POEM and EASI), duration of AD, use of other 
corticosteroid (ie, nasal, inhaled, oral) and QoL (IDQoL, 
CDLQI).
The secondary outcomes for the cohort will be analysed 
with descriptive statistics (ie, disease severity, frequency of 
flare-ups, medication use, healthcare use, QoL). Analyses 
to determine what the determinants of flare-ups of AD 
are after 1-year follow-up will be performed with logistic 
regression analyses.
Ethics and dissemination
Amendments are changes made to the research protocol 
after a favourable opinion from the accredited MEC. All 
substantial amendments will be notified to the MEC and 
to the competent authority.
The results of the study will be published in interna-
tional peer-reviewed journals and presented at (inter)
national conferences. We aim to publish several peer-re-
viewed publications on the best treatment strategy in 
children with AD related to patient-oriented outcomes, 
healthcare consumption and side effects. The results of 
this study may be implemented into clinical practice and/
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or can be used for the next update of the Dutch guideline 
on AD for GPs.
safety reporting
In accordance to section 10, subsection 4, of the Medical 
Research Involving Human Subjects Act (in Dutch: Wet 
Medisch-wetenschappelijk Onderzoek met Mensen), 
the sponsor will suspend the study if there is sufficient 
ground that continuation of the study will jeopardise 
subject health or safety. The sponsor will notify the 
accredited Medical research ethics committee (MREC) 
without undue delay of a temporary halt including the 
reason for such an action. The study will be suspended 
pending a further positive decision by the accredited 
MREC. The investigator will take care that all subjects are 
kept informed.
Monitoring
Due to the characteristics of this study it is not necessary 
to instal a data safety monitoring board. Nevertheless, 
the study will be monitored as described in the Interna-
tional Council for Harmonisation-Good Clinical Practice 
(ICH-GCP) guidelines (chapter 5.18). The department 
of general practice has developed a monitoring plan 
and monitoring checklist (based on the ICH-GCP guide-
lines) which will be used in this study. A senior researcher 
(project leader) will be designated as monitor. This 
senior researcher is not related to the current project and 
is part of another research discipline within the depart-
ment. At various moments in the study (not known to the 
researcher in front) an appointment will be made with 
the researcher and project leader of the current project 
to monitor the study by making use of the checklist of the 
department of general practice.
Adverse events
All (serious) adverse events and suspected unexpected 
serious adverse reactions reported spontaneously by the 
subject or observed by the investigator or the staff will be 
recorded.
dIsCussIon
This will be the first study to investigate the effectiveness 
of treatment with TCS class I versus class III on long-term 
control over 6 months follow-up of children in primary 
care with AD.
We chose an observational cohort design with an 
embedded pragmatic randomised open-label trial, as 
it might be difficult to randomise children in primary 
care at the moment they present with a flare-up. The 
observational cohort gives the opportunity to follow the 
course of AD in children in primary care with regard 
to the frequency and determinants of flare-ups and the 
burden of disease. As primary outcome, we chose a clin-
ical outcome relevant to patients. In AD, the appearance 
of the skin does not always closely reflect the subjective 
symptoms, that is, when the latter causes a major impact 
on the child and family.9 10 Therefore, it was particularly 
important to design a trial with a validated participant-re-
ported primary outcome.
The structure of regular home visits will probably artifi-
cially improve treatment adherence. It is generally known 
that treatment adherence is highest immediately after 
seeing a doctor.26 Both treatment arms will receive home 
visits, so this effect will be equally spread. The home 
visits will influence the generalisability of the results. 
However, it is crucial for several outcome measures to 
visit the patients. We kept the frequency of home visits 
to a minimum, balancing the unwanted effect of better 
treatment adherence and gathering important informa-
tion on study outcomes.
A limitation of the study is the open-label design. Since 
participants know which treatment arm they will be 
assigned to, they cannot be blinded to the intervention. 
Also, because the GP must be able to adjust the treatment 
strategy or refer to the child if required, the GP cannot be 
blinded. The research assistants will also be aware of the 
medication use of the child, as they have to register and 
weigh the medication.
Given that our primary outcome is patient reported, 
the additional costs for blinding researchers to collect the 
objective data (ie, EASI) did not seem justifiable.
Concerns have been reported about the safety of TCS 
application in children with regard to incorrect appli-
cation.27 Potential local side effects of TCS are painful 
application, telangiectasia, atrophy, hypopigmentation 
and striae. However, there is a lack of evidence from good 
quality research concerning these local side effects of 
TCS.28 Nevertheless, in a study on children with AD with 
a follow-up of 18 weeks, no difference was found in skin 
atrophy in children using class-III TCS for 3 days per week 
versus children using class I TCS.16 Potential systemic 
effects of TCS may include suppression of the HPA axis, 
and osteoporosis, glaucoma, cataract and growth reduc-
tion. Although there is lack of evidence about these 
potential systemic side effects, it is reported that topical 
TCS has little to no effect on the HPA axis, osteoporosis 
and growth reduction.12 14 15 29 In addition, the treatment 
scheme for the class III TCS is within the recommended 
dosage of the Dutch guideline on AD.12 Additionally, we 
want to include children of all ages with AD on most wide-
spread areas. Therefore, we chose a strong topical corti-
costeroid with the most favourable profile, this is found 
in fluticasone propionate 0.05% or 0.005% since it has 
a relatively short half-life as compared with the class III 
TCS that is recommended by the Dutch guideline (ie, 
betamethasone).12
In this way, we aim to further reduce the already low 
risk of potential (systemic) side effects; therefore, we 
believe that it is safe to use a class III TCS according to 
the previously described treatment scheme.
Experience from dermatologists indicates that starting 
with a high-dose TCS leads to a faster and better result 
as compared with starting with a low-dose TCS. However, 
most children with AD are treated by a GP (only about 1% 
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is referred to secondary care) and have a milder form of 
AD as compared with patients treated by a dermatologist.2 
Whether the effects of initial treatment with a potent TCS 
as experienced in a specialist setting can be transferred to 
treatment in primary care is unknown. Since the present 
study will focus on these gaps, it will hopefully make an 
important contribution to knowledge with respect to the 
use of local corticosteroids in children with AD treated in 
general practice.
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